Oregon Public Employees Retirement Fund Sells 517 Shares of ABIOMED, Inc. (NASDAQ:ABMD)

Oregon Public Employees Retirement Fund trimmed its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 9.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,795 shares of the medical equipment provider’s stock after selling 517 shares during the period. Oregon Public Employees Retirement Fund’s holdings in ABIOMED were worth $1,249,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. grew its position in ABIOMED by 314.3% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 648,206 shares of the medical equipment provider’s stock valued at $185,120,000 after acquiring an additional 491,750 shares during the period. Kayne Anderson Rudnick Investment Management LLC grew its position in ABIOMED by 78.6% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 13,934 shares of the medical equipment provider’s stock valued at $3,980,000 after acquiring an additional 6,134 shares during the period. Marshall Wace LLP grew its position in ABIOMED by 36.6% in the first quarter. Marshall Wace LLP now owns 4,549 shares of the medical equipment provider’s stock valued at $1,299,000 after acquiring an additional 1,219 shares during the period. Country Trust Bank grew its position in ABIOMED by 11.1% in the first quarter. Country Trust Bank now owns 106,931 shares of the medical equipment provider’s stock valued at $30,538,000 after acquiring an additional 10,667 shares during the period. Finally, IFM Investors Pty Ltd grew its position in ABIOMED by 6.8% in the first quarter. IFM Investors Pty Ltd now owns 2,655 shares of the medical equipment provider’s stock valued at $758,000 after acquiring an additional 170 shares during the period. Hedge funds and other institutional investors own 87.90% of the company’s stock.

A number of brokerages have weighed in on ABMD. SunTrust Banks reiterated a “buy” rating and issued a $340.00 price target on shares of ABIOMED in a research report on Friday, May 3rd. Guggenheim cut ABIOMED from a “buy” rating to a “neutral” rating in a report on Friday. BTIG Research cut ABIOMED from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. BidaskClub upgraded ABIOMED from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 24th. Finally, ValuEngine cut ABIOMED from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. ABIOMED has an average rating of “Hold” and a consensus target price of $316.50.

In related news, Director Martin P. Sutter sold 4,664 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $259.97, for a total value of $1,212,500.08. Following the transaction, the director now owns 192,550 shares in the company, valued at $50,057,223.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by company insiders.

Shares of ABMD stock traded up $0.89 during trading hours on Tuesday, hitting $205.42. 8,888 shares of the company’s stock were exchanged, compared to its average volume of 623,944. The company has a 50-day moving average price of $256.16. The firm has a market cap of $9.26 billion, a PE ratio of 56.66, a price-to-earnings-growth ratio of 1.62 and a beta of 0.31. ABIOMED, Inc. has a 52 week low of $197.01 and a 52 week high of $459.75.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 EPS for the quarter, topping the consensus estimate of $0.99 by $0.01. The company had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. The business’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.95 earnings per share. On average, equities analysts anticipate that ABIOMED, Inc. will post 4.41 earnings per share for the current year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: Investing in Dividend Stocks

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.